AstraZeneca stock price forecast: GBX13,890.50 resistance as AZN trades sideways

Traders Union
All News
Financial News
AstraZeneca up 0.93% at GBX13,666.00

Highlights

AstraZeneca gained approval to market Enhertu for first-line HER2-positive breast cancer in India, expanding oncology revenue potential.
Phase II results for AstraZeneca's oral GLP-1 candidate showed up to 10.5% weight loss, indicating promising pipeline momentum.
Despite strong price action near GBX13,666.00, technicals signal overbought conditions with high risk of a short-term pullback below support.

Market expansion and pipeline progress drive sentiment amid regulatory delays

AstraZeneca recently received approval from the Central Drugs Standard Control Organization to import and market Trastuzumab deruxtecan (Enhertu) for first-line treatment of HER2-positive breast cancer in India, directly expanding its access to a significant new market and increasing potential revenue from oncology therapeutics. The company also shared data at the American Diabetes Association 86th Scientific Sessions, displaying ongoing engagement with the medical community and reinforcing its profile within metabolic and endocrine therapy fields. Additional progress in clinical trials for its oral GLP-1 pill, with Phase II results showing up to 10.5% weight loss, highlights further opportunities, while an extended FDA review for camizestrant introduces a timing delay to potential US revenue from this candidate.

Mixed momentum and resistance divergence as intraday signals conflict

On the hourly chart, AZN is positioned above the MA-20 and MA-50, while also maintaining levels above the MA-200 on the daily timeframe. The Ichimoku Kijun provides immediate support at GBX13,553.00. Intraday indicator readings remain mixed: MACD and ADX indicate selling momentum, while RSI is in Sell territory. Stoch RSI and CCI sit in neutral zones, with BBP signaling an overbought condition, suggesting strong buyer dominance intraday. The Awesome Oscillator is neutral and does not confirm current downside momentum, leaving a notable divergence between price strength and underlying momentum signals.

Consolidation likely as downside risk prevails without catalyst

Over the next 2–3 trading days, AZN is expected to consolidate within a price range of GBX13,441.50 to GBX13,890.50, reflecting a typical volatility band relative to current levels. Downside scenarios predominate, with a high likelihood of the price moving lower if immediate support is breached, while upside moves appear less probable without a break above the upper end of the range. The baseline scenario involves continued consolidation within this corridor unless a catalyst triggers a decisive trend shift.

Viktoras Karapetjanc, expert at Traders Union, sees solid fundamental momentum in AstraZeneca PLC after the key regulatory approval in India and visible pipeline progress. He notes the bullish sentiment supported by the stock trading above major moving averages, though some technical divergence limits immediate upside. The analyst believes consolidation within GBX13,441.50 to GBX13,890.50 is probable near term, but the strong macro and clinical backdrop favors longer-term confidence. 'Approval progress and new market entry keep the growth story alive — I see tactical consolidation as an opportunity for patient buyers.'

Earlier, analysts noted that AstraZeneca's technical indicators were showing ongoing bearish momentum, with caution prevailing among traders despite underlying strength in the company’s clinical pipeline. The recent shift to sustained bullish price action, supported by positive regulatory and clinical developments, adds a new dimension to the outlook, suggesting traders should now monitor for a potential upside breakout if the stock maintains its position above immediate support levels.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.